Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Acute Myeloid Leukemia With KMT2A Rearrangement”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Looking for participantsNCT07155226
What this trial is testing

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Who this might be right for
Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic Syndromes
AstraZeneca 84
Testing effectiveness (Phase 2)Looking for participantsNCT04065399
What this trial is testing

Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute Leukemia+2 more
Syndax Pharmaceuticals 447
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Sumitomo Pharma America, Inc. 362
Early research (Phase 1)Study completedNCT05326516
What this trial is testing

Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Who this might be right for
Relapsed/Refractory LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic Leukemia+3 more
Syndax Pharmaceuticals 30
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Early research (Phase 1)Looking for participantsNCT06001788
What this trial is testing

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AMLAML With Mutated NPM1Hematologic Malignancy+9 more
Kura Oncology, Inc. 171
Testing effectiveness (Phase 2)Active Not RecruitingNCT06052813
What this trial is testing

BN104 in the Treatment of Acute Leukemia

Who this might be right for
ALL, AdultAML, AdultAcute Leukaemia+4 more
Institut de Recherches Internationales Servier (I.R.I.S.) 66
Early research (Phase 1)Study completedNCT02141828
What this trial is testing

Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

Who this might be right for
LeukemiaAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+1 more
Epizyme, Inc. 18
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Testing effectiveness (Phase 2)Ended earlyNCT03724084
What this trial is testing

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Who this might be right for
Acute Myeloid Leukemia
National Cancer Institute (NCI) 6
Early research (Phase 1)Not Yet RecruitingNCT07355335
What this trial is testing

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Who this might be right for
KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
Massachusetts General Hospital 24
Early research (Phase 1)Looking for participantsNCT05886049
What this trial is testing

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Who this might be right for
Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
National Cancer Institute (NCI) 28